Advances in neoadjuvant therapy for breast cancer at the ASCO annual meeting
10.12354/j.issn.1000-8179.2025.20241492
- VernacularTitle:乳腺癌新辅助治疗美国临床肿瘤学年会进展报道
- Author:
Shi XIUQING
1
;
Yuan PENG
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科(北京市 100021)
- Publication Type:Journal Article
- Keywords:
breast cancer;
neoadjuvant therapy;
biomarker
- From:
Chinese Journal of Clinical Oncology
2025;52(3):154-160
- CountryChina
- Language:Chinese
-
Abstract:
Recent progress in the field of breast cancer research was reported at the American Society of Clinical Oncology(ASCO)annual meeting.Research on neoadjuvant therapy for breast cancer represents the current main approach,such as finding different chemothera-peutic regimens to enhance efficacy and improve prognosis,developing treatment strategies for patients who do not achieve pathological complete response(non-pathologic complete response,non-pCR)after neoadjuvant therapy,and exploring predictive biomarkers or tools for efficacy and prognosis.In this article,we report related research progress in neoadjuvant therapy for different subtypes of breast cancer in ASCO 2024 to present the current overall landscape of neoadjuvant therapy and provide a reference for clinical decision-making.
